• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
```
Home»Posts tagged with»neurorehabilitation

How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation

By Soujanya Ravi on May 13, 2026   Pharma & Biotech  

How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation

How is PharmAla Biotech Holdings Inc. positioning APA-01 for traumatic brain injury and neurorehabilitation markets? Read the full PDN analysis.

Merz Therapeutics tests the long game in neurorehabilitation with XEOMIN data

By Pallavi Madhiraju on May 13, 2026   Pharma & Biotech  

Merz Therapeutics tests the long game in neurorehabilitation with XEOMIN data

Spasticity care is not one injection cycle. Merz Therapeutics is pushing XEOMIN data toward durability, dosing flexibility and patient goals.

Recent Posts

  • Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
  • Nippon Shinyaku backs EXG-7001 as full-length dystrophin mRNA strategy enters Duchenne race
  • Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?
  • Lupin’s tentative FDA approval for enzalutamide sets up a high-value generic challenge to Xtandi
  • Why LEO Pharma is shifting the chronic hand eczema debate from skin clearance to life impact
  • Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows
  • Why Natera’s Prospera could reshape how Eledon measures kidney transplant injury in Phase 3
  • Merck and Gilead secure FDA approval for a new ADC-immunotherapy backbone in advanced TNBC
  • How Johnson & Johnson’s dual-energy THERMOCOOL platform could reshape European atrial fibrillation ablation
  • Gilead expands Trodelvy into first-line metastatic TNBC, but survival questions remain unresolved
  • Ionis Pharmaceuticals moves beyond rare disease as Tryngolza enters the wider triglyceride market
  • Pfizer’s Ibrance wins broader FDA role as metastatic breast cancer treatment becomes more complex
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes